<DOC>
	<DOCNO>NCT01674075</DOCNO>
	<brief_summary>The J-Tip device ( National Medical Products , Irvine , CA , USA ) single-use , needle-free anesthesia delivery system , approximately 10cm long weigh 9g allow rapid delivery lidocaine hydrochloride prior peripheral venous access procedure . First introduced 2001 , use compressed carbon dioxide drug delivery subcutaneous space . J-Tip approve U.S. Food Drug Administration ( FDA ) child adult . Designed patient needle anxiety phobia , several clinical trial ( Hollingsworth et al , 2000 ; Cooper JA et al , 2000 ) show device effective significant untoward effect , include child young 3 year old ( Zempsky et al , 2008 ) . However , two recent case toxic serum lidocaine level pediatric patient Massachusetts General Hospital ( MGH ) follow use J-Tip device concerning . Both patient administer local anesthetic use J-Tip device prior needle-stick toxicity screen return high level lidocaine ( &gt; 6000 mcg/L ) . Currently , limit amount literature available safety profile J-Tip Delivery System study date evaluate serum lidocaine level follow use , likely assumption systemic absorption small amount lidocaine within device negligible . The two pediatric case highlight , seem suggest otherwise . The purpose pilot study assess safety J-Tip device small population healthy adult determine elevate lidocaine level present systemically locally . The primary outcome lidocaine serum level follow administration J-Tip device measure local site two distal site establish lidocaine serum level follow J-Tip administration . We expect lidocaine level undetectable .</brief_summary>
	<brief_title>Lidocaine Serum Levels Healthy Adult Volunteers : Pilot Evaluation J-Tip Delivery System</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria 1 . Adults ( 1859 year old ) without know medical illness 2 . Subject capacity provide inform consent Exclusion Criteria 1 . Individuals recently receive `` caine '' ( dental procedure , topical ( orajel ) hydrocortisone/lidocaine cream ) exclude study 2 . History liver kidney problem 3 . Individuals receive chemotherapeutic agent 4 . Individuals PORTACATHÂ® Implantable Vascular Access System</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>safety</keyword>
	<keyword>J-Tip Delivery System</keyword>
	<keyword>pharmacokinetic profile</keyword>
</DOC>